Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg

Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg

Blood High Pressure

Aortic Dissection Type B

Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.

Urapidil Hydrochloride Injection

Sir Run Run Shaw Hospital

Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection

Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection (RAID): Study Protocol for Randomized Controlled Trial

including death, permanent paraplegia or semi- paralysis during the hospitalization, and renal failure requiring hemodialysis at discharge

any intervention for the same situation such as operation or endovascular intervention

Jian-cang Zhou M.D.

Principal Investigator

Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.
60 patients with organic brain syndrome will receive their first doses (n=2-3) of auto-M2-BFs in clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose.
The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment.

Organic Brain Syndrome, Nonpsychotic

Neurocognitive Disorders

Mental Disorder, Organic

Delirium, Dementia, Amnestic, Cognitive Disorders

Nonpsychotic Organic Brain Syndrome

Organic Mental Disorder

Encephalopathy, Post-Traumatic, Chronic

Encephalopathy, Ischemic

Brain Ischemia

Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.

Intranasal auto-M2-BFs

Institute of Fundamental and Clinical Immunology

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by Autologous M2 Macrophages in Patients With Organic Brain Syndrome

Occurrence of adverse events including allergic, toxic, inflammatory reactions; neurological worsening; seizures

Alexander A Ostanin

Russian Academy of Medical Sciences

Chronic Focal Encephalitis

Rasmussen's Encephalitis

375 mg/m2 given as an IV infusion once weekly for four doses

paresis/nekros

Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen